Jurnal 2014-3.pdf
Jan 21, 2022
3200 words / 16315 characters

Masayoshi Arai

Jurnal 2014-3.pdf

Sources Overview

19%
OVERALL SIMILARITY

#	Source	Type	Similarity
1	Yoshi Yamano, Masayoshi Arai, Motomasa Kobayashi. "Neamphamide B, new cyclic depsipeptide, as an anti-dormant mycobacterial su...	CROSSREF	3%
2	www.mysciencework.com	INTERNET	3%
3	Kentaro Kamiya, Masayoshi Arai, Andi Setiawan, Motomasa Kobayashi. " Anti-dormant Mycobacterial Activity of Viomellein and Xantho...	CROSSREF	2%
4	Masayoshi Arai, Yoshi Yamano, Andi Setiawan, Motomasa Kobayashi. "Identification of the Target Protein of Agelasine D, a Marine Spon...	CROSSREF	1%
5	Shunji Aoki, Mami Sanagawa, Yasuo Watanabe, Andi Setiawan, Masayoshi Arai, Motomasa Kobayashi. "Novel isomarabarican triterpene...	CROSSREF	1%
6	Masayoshi Arai, Kentaro Kamiya, Patamaporn Pruksakorn, Yuji Sumii et al. "Anti-dormant mycobacterial activity and target analysis of n...	CROSSREF	1%
7	Bing-Nan Han, Li-Li Hong, Bin-Bin Gu, Yang-Ting Sun, Jie Wang, Jin-Tang Liu, Hou-Wen Lin. "Chapter 15 Natural Products from Sponge...	CROSSREF	<1%
8	Masayoshi Arai, Yoshi Yamano, Mayumi Fujita, Andi Setiawan, Motomasa Kobayashi. "Stylissamide X, a new proline-rich cyclic octape...	CROSSREF	<1%
9	mafiadoc.com	INTERNET	<1%
10	H. Jiang. "Potent and selective inhibitors of Staphylococcus epidermidis tryptophanyl-tRNA synthetase", Journal of Antimicrobial Che...	CROSSREF	<1%
11	Qianqian He, Shuang Miao, Na Ni, Yuqing Man, Kaikai Gong. " A Review of the Secondary Metabolites From the Marine Sponges of the...	CROSSREF	<1%
12	www.pubmedcentral.nih.gov	INTERNET	<1%
13	Arai, Masayoshi, Shunsuke Ishida, Andi Setiawan, and Motomasa Kobayashi. "Haliclonacyclamines, Tetracyclic Alkylpiperidine Alkaloi...	CROSSREF	<1%
14	Yuji Sumii, Naoyuki Kotoku, Chisu Han, Kentaro Kamiya, Andi Setiawan, Catherine Vilchèze, William R. Jacobs, Masayoshi Arai. "3-(Phe...	CROSSREF	<1%
15	www.jstage.jst.go.jp	INTERNET	<1%
16	link.springer.com	INTERNET	<1%
17	www.ajol.info	INTERNET	<1%

Excluded search repositories:

None

Excluded from document:

Bibliography

Quotes

Citations

Small Matches (less than 10 words)

Excluded sources:

repository.lppm.unila.ac.id, internet, 59%

Masayoshi Arai, Chisu Han, Yoshi Yamano, Andi Setiawan, Motomasa Kobayashi. "Aaptamines, marine spongean alkaloids, as anti-dormant mycobacterial substances", Journal of Natural Medicines, 2014, crossref, 58%

www.science.gov, internet, 5%

www.jove.com, internet, 5%

linknovate.com, internet, 5%

worldwidescience.org, internet, 5%

Hao-Bing Yu, Fan Yang, Fan Sun, Guo-Yi Ma, Jian-Hong Gan, Wen-Zhen Hu, Bing-Nan Han, Wei-Hua Jiao, Hou-Wen Lin. " Cytotoxic Aaptamine Derivatives from the South China Sea Sponge ", Journal of Natural Products, 2014, crossref, 5%

J Nat Med
DOI 10.1007/s11418-013-0811-y



ORIGINAL PAPER

Aaptamines, marine spongean alkaloids, as anti-dormant mycobacterial substances

Masayoshi Arai · Chisu Han · Yoshi Yamano · Andi Setiawan · Motomasa Kobayashi

Received: 16 November 2013 / Accepted: 16 December 2013
© The Japanese Society of Pharmacognosy and Springer Japan 2014

Abstract A new aaptamine class alkaloid, designated 2-methoxy-3-oxoaaptamine (**1**), together with seven known aaptamines (**2**–**8**) were isolated from a marine sponge of *Aaptos* sp. as anti-mycobacterial substances against active and dormant bacilli. The chemical structure of **1** was determined on the basis of spectroscopic analysis. Compound **1** was anti-mycobacterial against *Mycobacterium smegmatis* in both active growing and dormancy-inducing hypoxic conditions with a minimum inhibitory concentration (MIC) of 6.25 μg/ml, and compounds **2**, **5**, **6**, and **7** showed anti-mycobacterial activities under hypoxic condition selectively, with MIC values of 1.5–6.25 μg/ml.

Keywords Aaptamine · Marine sponge · Anti-mycobacterial activity · Dormant · Tuberculosis

Introduction

Tuberculosis (TB) is one of the most common causes of morbidity and mortality in HIV-positive adults living in poverty [1]. In 2011, there were an estimated 8.7 million new TB cases and 1.4 million deaths by TB [2]. It is now generally accepted that a minimum of 6 months of TB treatment is required owing to the difficulty of eradicating non-replicating persistent *Mycobacterium tuberculosis*. Therefore, new lead compounds which exhibit anti-bacterial activity against *M. tuberculosis* in both its active and dormant states are urgently needed. Although the physiology of latent *M. tuberculosis* infection is still unclear, hypoxic conditions have been found to induce the dormant state of *Mycobacterium* sp., which has a drug-susceptibility profile resembling that of latent *M. tuberculosis* infection [3–5]. Based on this background, we established a screening system to search for substances that have anti-bacterial activity against dormant mycobacteria, and isolated halicyclamines [6, 7] (macrocyclic alkaloids) from a marine sponge of *Haliclona* sp., trichoderins [8] (new aminolipopeptides) from a culture of marine sponge-derived fungus of *Trichoderma* sp., and neamphamide B [9] (a new cyclic depsipeptide) from a marine sponge of *Neamphius* sp. on the basis of bioassay-guided separation. In the continuing screening of marine organisms, a new aaptamine class alkaloid, named 2-methoxy-3-oxoaaptamine (**1**), together with seven known aaptamines (**2**–**8**) were isolated from an Indonesian marine sponge of *Aaptos* sp. In this paper, we present the structure elucidation of compound **1** and the anti-microbial activity against *M. smegmatis* of the compounds isolated.

M. Arai (✉) · C. Han · Y. Yamano · M. Kobayashi (✉)
Graduate School of Pharmaceutical Sciences, Osaka University, Yamada-oka 1-6, Suita, Osaka 565-0871, Japan
e-mail: araim@phs.osaka-u.ac.jp

M. Kobayashi
e-mail: kobayasi@phs.osaka-u.ac.jp

A. Setiawan
Department of Chemistry, Faculty of Science, Lampung University, Jl. Prof. Dr. Sumantri Brodjonegoro No. 1, Tanjungkarang 35145, Indonesia

Materials and methods

General experimental procedures

NMR (600 MHz for ^{1}H-NMR, 150 MHz for ^{13}C-NMR, referenced to TMS) spectra were measured on a Varian Unity Inova 600 (Varian). Electrospray ionization time-of-flight mass spectrometry (ESI-TOF–MS) was recorded on a

Published online: 12 January 2014

1/21/22, 8:49 PM Jurnal 2014-3.pdf - Masayoshi Arai

Q-Tof Ultima (Waters Co.). IR spectra were obtained with a Jasco FT/IR-5300 (KBr pellets). Column chromatography was performed on silica gel 60N (63–210 µm, Kanto Chemical Co., Inc., Tokyo, Japan). TLC analysis was carried out by silica gel 60F_{254} (Merck Chemical, Darmstadt, Germany). HPLC was performed by a Hitachi High Sensitivity Series system (UV detector: L-4000H) with Cosmosil 5C18-AR-II column (5 µm, 20 mm i.d. × 250 mm, Nacalai tesque, Kyoto, Japan) and Capcellpak MGII S5 (5 µm, 10 mm i.d. × 250 mm, Shiseido Co., Ltd., Tokyo, Japan). Other chemicals were purchased from Sigma (St. Louis, MO, USA) or Nacalai tesque (Kyoto, Japan).

Extraction and isolation of active compounds

The dried marine sponge (400 g), which was collected in 2009 at Kupang, Indonesia, was extracted with MeOH. The MeOH extract [32 g, minimum inhibitory concentration (MIC) against *M. smegmatis* = 200 µg/ml (aerobic condition), 100 µg/ml (hypoxic condition)] was then partitioned by the alkaloid extraction procedure [10]. Using bioassay guidance, the alkaloid fraction [2 g, MIC = 6.25 µg/ml (aerobic condition), 6.25 µg/ml (hypoxic condition)] was subjected to silica gel column chromatography [eluted with $CHCl_3$:MeOH:H_2O (lower phase) containing 0.1 % triethylamine] to obtain nine fractions (Fr. A1–Fr. A9). Of the nine fractions, Fr. A2 and A3 [eluted with $CHCl_3$:MeOH:H_2O = 65:3:1 (lower phase) containing 0.1 % triethylamine], and A6 [eluted with $CHCl_3$:MeOH:H_2O = 15:3:1 (lower phase) containing 0.1 % triethylamine] showed potent anti-microbial activity against *M. smegmatis* under both aerobic and hypoxic conditions.

The active Fr. A2 [15.8 mg, MIC = 6.25 µg/ml (aerobic condition), 3.13 µg/ml (hypoxic condition)] was purified by ODS-HPLC [Capcellpak MGII S5, 10 mm i.d. × 250 mm, a linear gradient from 40 % MeOHaq. to 100 % MeOH over 30 min] to provide 2-methoxy-3-oxoaaptamine (**1**, 0.7 mg) and demethyl(oxy)aaptamine [11] (**5**, 1.0 mg). The active Fr. A3 [67.9 mg, MIC = 6.25 µg/ml (aerobic condition), 3.13 µg/ml (hypoxic condition)] was further separated by ODS-HPLC [Cosmosil 5C18-AR-II, 20 mm i.d. × 250 mm, a linear gradient from 40 % MeOHaq. to 100 % MeOH over 30 min] to give 2,3-dihydro-2,3-dioxoaaptamine [12] (**2**, 1.4 mg), compound **4** [13] (2.7 mg), 3-(methylamino)demethyl(oxy)aaptamine [12] (**7**, 2.2 mg), and compound **8** [13] (1.2 mg). Moreover, the active Fr. A6 [146.9 mg, MIC = 1.75 µg/ml (aerobic condition), 12.5 µg/ml (hypoxic condition)] was then purified by ODS-HPLC [Capcellpak MGII S5, 10 mm i.d. × 250 mm, a linear gradient from 20 % MeOHaq. to 100 % MeOH over 30 min] to afford aaptamine [14] (**3**, 5.3 mg) and 3-aminodemethyl(oxy)aaptamine [15] (**6**, 2.4 mg) (Fig. 1). Each known compound was identified by ESI-TOF–MS and 2D-NMR analysis and comparison with authentic spectral data [11–15].

2-Methoxy-3-oxoaaptamine (1): Yellow amorphous solid. IR ν_{max} (KBr) cm^{-1}: 2,926, 1,870, 1,487, 1,282, 1,086. UV λ_{max} (MeOH) nm (ε): 244 (3,500), 258 (2,200), 271 (2,300), 312 (5,850). ESI-TOF–MS: *m/z* 295 $[M + Na]^+$. High resolution (HR)-ESI-TOF–MS: Calcd for $C_{14}H_{12}N_2O_4Na$: *m/z* 295.0695. Found 295.0677. ^1H-NMR (600 MHz, DMSO-d_6, δ_H), ^{13}C-NMR (150 MHz, DMSO-d_6, δ_C) spectra: as shown in Table 1.

Bacterial culture

Mycobacterium smegmatis mc^{2}155 was grown in Middlebrook 7H9 broth (BD, Franklin, NJ, USA) containing 10 % OADC (BD), 0.5 % glycerol and 0.05 % Tween 80 or on Middlebrook 7H10 agar (BD) containing 10 % OADC and 0.5 % glycerol.

Determination of MIC values under aerobic and hypoxic conditions

Determination of MIC values against *M. smegmatis* was performed by the established MTT method [16]. Mid-log phase of *M. smegmatis* (1 × 10^4 CFU/0.1 ml) was inoculated in 96-well plates, and then serial diluted samples were



Fig. 1 Chemical structures of the isolated compounds **1–8**

https://unila.turnitin.com/viewer/submissions/oid:7867:12757419/print?locale=en 4/7

Table 1 ^{1}H- and ^{13}C-NMR data for **1**

Position	δ_C^a	δ_H^b
2	156.3	
3-CO	172.0	
3a	144.3	
5	146.4	8.85 (d, $J = 4.8$)
6	125.0	8.07 (d, $J = 4.8$)
6a	134.2	
7	105.1	7.45 (s)
8	156.6	
9	149.0	
9a	125.3	
9b	119.4	
2-OCH$_3$	54.7	4.01 (s)
8-OCH$_3$	56.8	3.97 (s)
9-OCH$_3$	63.6	4.38 (s)

[a] ^{13}C-NMR: δ_C (ppm), (150 MHz, DMSO-d_6)

[b] ^{1}H-NMR: δ_H (ppm, J in Hz), (600 MHz, DMSO-d_6)

added to the 96-well plate. For aerobic conditions, the bacteria were incubated at 37 °C for 24 h, whereas the hypoxic model was performed based on the description by Rustad et al. [17] with minor modification. The mycobacterial bacilli were grown in Middlebrook 7H9 broth at 37 °C under nitrogen atmosphere containing 0.2 % oxygen until the optical density reached 0.8 at 600 nm. The bacilli were then inoculated to the 96-well plate at the same density as the aerobic condition and incubated at 37 °C under nitrogen atmosphere containing 0.2 % oxygen for 96 h. After incubation, 50 µl of MTT solution (0.5 mg/ml) was added into each well and incubated at 37 °C for an additional 12 h under aerobic or hypoxic conditions. The optical density at 560 nm was measured to determine the MIC value.

Results and discussion

The MeOH extract (32 g) of the dried marine sponge of *Aaptos* sp. showed anti-microbial activity against *M. smegmatis* in both active growing aerobic condition and dormancy-inducing hypoxic condition. From a preliminary result obtained by bioautography [18, 19] suggesting that the active constituents might be alkaloidal compounds, the MeOH extract was fractionated by the alkaloid extraction procedure [10]. Using bioassay guidance, the alkaloid fraction (2 g) was further fractionated by silica gel column chromatography and ODS-HPLC to afford compound **1** (0.7 mg, 0.035 % yield from the alkaloid fraction) together with 2,3-dihydro-2,3-dioxoaaptamine (**2**, 1.4 mg, 0.07 %) [12], aaptamine (**3**, 5.3 mg, 0.27 %) [14], dimethyl ketal



Fig. 2 HMBC and ROESY correlations for **1**

derivative of demethyl(oxy)aaptamine (**4**, 2.7 mg, 0.14 %) [13], demethyl(oxy)aaptamine (**5**, 1.0 mg, 0.05 %) [11], 3-aminodemethyl(oxy)aaptamine (**6**, 2.4 mg, 0.12 %) [15], 3-(methylamino)demethyl(oxy)aaptamine (**7**, 2.2 mg, 0.11 %) [12], and compound **8** (1.2 mg, 0.06 %) [13] (Fig. 1). Of them, compound **4** having the dimethyl ketal moiety is assumed to be an artifact product from compound **5** in the isolation process [20].

Compound **1** was obtained as a yellow amorphous solid. The ESI-TOF–MS of **1** showed a quasi-molecular ion peak $[M + Na]^+$ at m/z 295, and the molecular formula was determined as $C_{14}H_{12}N_2O_4$ by high-resolution (HR-) ESI-TOF–MS. In the ^{1}H-NMR spectrum of **1**, the signals observed at δ_H 8.07 and 8.85 (each 1H, d, $J = 4.8$ Hz), along with one isolated singlet at δ_H 7.45 (1H, s), resembled with those of aaptamine alkaloids having benzo[*de*][1, 6]naphthyridine skelton. Compound **1** also exhibited three methoxyl signals observed at δ_H 3.97, δ_H 4.01, and δ_H 4.38 (each 3H, s). In addition, the IR absorptions at 1,670 cm^{-1} and the signal at 172.0 ppm in the ^{13}C-NMR spectrum suggested the presence of a carbonyl group. Then, the HMBC correlations between δ_H 3.97 and δ_C 156.6 (C-8); δ_H 4.38 and δ_C 149.0 (C-9) suggested that two of the three methoxyl groups were positioned at C-8 and C-9. The ROESY correlations from H-5 (δ_H 8.85) and H-7 (δ_H 7.45) to H-6 (δ_H 8.07); from the methoxyl proton (δ_H 4.38) and H-7 (δ_H 7.45) to the other methoxyl proton (δ_H 3.97) also supported the positions of these methoxyl groups (Fig. 2). In addition, the ten unsaturations and the HMBC correlation between δ_H 4.01 and δ_C 156.3 (C-2) as shown in Fig. 2 provided the chemical structure (2-methoxy-3-oxoaaptamine) for compound **1**. All the proton and carbon signals were assigned as shown in Table 1.

It is well known that these benzonaphthyridine alkaloids show various biological properties such as α-adrenoreceptor antagonistic, anti-microbial, anti-proliferative, anti-protozoal, and anti-viral activities [21]. Our group have also reported that aaptamine (**3**) activated p21 promoter

Table 2 MIC of aaptamines against *M. smegmatis* under aerobic and hypoxic conditions

Compounds	MIC (μg/ml)	
	Aerobic	Hypoxic
1	6.25	6.25
2	25	6.25
3	100	200
4	200	100
5	25	6.25
6	6.25	1.5
7	6.25	1.5
8	25	12.5
Isoniazid	2.5	25

stably transfected in human osteosarcoma cell MG63 in a p53-independent way [22]. To date, some semi-synthetic derivatives of aaptamine (**3**) and isoaaptamine [23] have been reported to exhibit growth inhibitory activity against *M. tuberculosis* or *M. intracellulare* under active growing condition, while no anti-mycobacterial activity has been reported for aaptamine (**3**) and other natural related compounds [24, 25].

On the other hand, hypoxia is known to be a major factor inducing a nonreplicating persistence of tubercule bacilli. Wayne et al. [3, 26] proved that oxygen depletion triggered the dormancy response, such as isoniazid resistance, in mycobacterial bacilli. Based on these observations, we established a screening system to search for substances that exhibit anti-bacterial activity against dormant mycobacteria. Indeed, the minimum inhibitory concentration (MIC) value of isoniazid against *M. smegmatis* is observed to be 2.5 μg/ml under aerobic conditions, whereas it shifted to 25 μg/ml under nitrogen atmosphere containing 0.2 % oxygen, as shown in Table 2. Compounds **1**–**8** were then examined for their anti-microbial effects against *M. smegmatis* using this assay system (Table 2). Under active growing aerobic condition, compounds **1**, **6**, and **7** showed potent anti-microbial activities with MIC values of 6.25 μg/ml, and compounds **2**, **5**, and **8** exhibited moderate activities with MIC values of 25 μg/ml. On the other hand, the activity of compounds **3** and **4** was very weak. Although further investigation is necessary for structure–activity relationship (SAR) studies, these observations suggest that the existence of the carbonyl group at the C-3 or C-9 positions would provide the positive effect for the anti-microbial activity against *M. smegmatis* under active growing condition. Interestingly, compounds **2**, **5**, **6**, and **7** exhibited anti-microbial activity against dormancy-induced *M. smegmatis* selectively, with MIC values of 6.25, 6.25, 1.5, and 1.5 μg/ml, respectively. Taken together, compounds **6** and **7** showed the most potent and selective anti-microbial activity, with MIC values of 6.25 and 1.5 μg/ml under aerobic condition and hypoxic condition, respectively (Table 2). Detailed evaluation using pathogenic *Mycobacterium* spp. and synthetic study of analog compounds for SAR analysis are in progress.

Acknowledgments This study was financially supported by the Hoansha Foundation and Grant-in-Aid for scientific research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

References

1. Idemyor V (2007) HIV and tuberculosis coinfection: inextricably linked liaison. J Natl Med Assoc 99:1414–1419
2. Global Tuberculosis report 2012 World Health Organization: Geneva, Switzerland. Available online: http://www.who.int/tb/publications/global_report/en/. Accessed on 10 November 2013
3. Wayne LG, Sohaskey CD (2001) Nonreplicating persistence of *Mycobacterium tuberculosis*. Annu Rev Microbiol 55:139–163
4. Lim A, Eleuterio M, Hutter B, Murugasu-Oei B, Dick T (1999) Oxygen depletion-induced dormancy in *Mycobacterium bovis* BCG. J Bacteriol 181:2252–2256
5. Dick T, Lee BH, Murugasu-Oei B (1998) Oxygen depletion induced dormancy in *Mycobacterium smegmatis*. FEMS Microbiol Lett 163:159–164
6. Arai M, Sobou M, Vilchèze C, Baughn A, Hashizume H, Pruksakorn P, Ishida S, Matsumoto M, Jacobs WR Jr, Kobayashi M (2008) Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent. Bioorg Med Chem 16:6732–6736
7. Arai M, Ishida S, Setiawan A, Kobayashi M (2009) Haliclonacyclamines, tetracyclic alkylpiperidine alkaloids, as anti-dormant mycobacterial substances from a marine sponge of Haliclona sp. Chem Pharm Bull 57:1136–1138
8. Pruksakorn P, Arai M, Kotoku N, Vilchèze C, Baughn AD, Moodley P, Jacobs WR Jr, Kobayashi M (2010) Trichoderins, novel aminolipopeptides from a marine sponge-derived *Trichoderma* sp., are active against dormant mycobacteria. Bioorg Med Chem Lett 20:3658–3663
9. Yamano Y, Arai M, Kobayashi M (2012) Neamphamide B, new cyclic depsipeptide, as an anti-dormant mycobacterial substance from a Japanese marine sponge of *Neamphius* sp. Bioorg Med Chem Lett 22:4877–4881
10. Kobayashi M, Kawazoe K, Kitagawa I (1989) Araguspongines B, C, D, E, F, G, H, and J, new vasodilative bis-1-oxaquinolizidine alkaloids from an Okinawan marine sponge, *Xestospongia* sp. Chem Pharm Bull 37:1676–1678
11. Nakamura H, Kobayashi J, Ohizumi Y, Hirata Y (1987) Physiologically active marine natural products from Prolifera. Part 10. Aaptamines. Novel benzo[de][1,6]naphthyridines from the Okinawan marine sponge *Aaptos aaptos*. J Chem Soc Perkin Trans 1:173–176
12. Shubina LK, Makarieva TN, Dyshlovoy SA, Fedorov SN, Dmitrenok PS, Stonik VA (2010) Three new aaptamines from the marine sponge *Aaptos* sp. and their pro apoptotic properties. Nat Prod Commun 5:1881–1884
13. Calcul L, Longeon A, Mourabit AA, Guyot M, Bourguet-Kondracki ML (2003) Novel alkaloids of the aaptamine class from an Indonesian marine sponge of the genus *Xestospongia*. Tetrahedron 59:6539–6544
14. Nakamura H, Kobayashi J, Ohizumi Y, Hirata Y (1982) Isolation and structure of aaptamine, a novel heteroaromatic substance

1/21/22, 8:49 PM Jurnal 2014-3.pdf - Masayoshi Arai

possessing α-blocking activity from the sea sponge *Aaptos aaptos*. Tetrahedron Lett 23:5555–5558

15. Pham CD, Hartmann R, Müller WEG, de Voogd N, Lai D, Proksch P (2013) Aaptamine derivatives from the Indonesian sponge *Aaptos suberitoides*. J Nat Prod 76:103–106
16. Abate G, Aseffa A, Selassie A, Goshu S, Fekade B, WoldeMeskal D, Miörner H (2004) Direct colorimetric assay for rapid detection of rifampin-resistant *Mycobacterium tuberculosis*. J Clin Microbiol 42:871–873
17. Rustad TR, Harrell MI, Liao R, Sherman DR (2008) The enduring hypoxic response of *Mycobacterium tuberculosis*. PLoS One 3:e1502
18. Wedge DE, Nagle DG (2000) A new 2D-TLC bioautography method for the discovery of novel antifungal agents to control plant pathogens. J Nat Prod 63:1050–1054
19. Runyoro DKB, Matee MIN, Ngassapa OD, Joseph CC, Mbwambo ZH (2006) Screening of Tanzanian medicinal plants for anti-candida activity. BMC Complement Altern Med 6:11–20
20. Pettit GR, Hoffmann H, McNulty J, Higgs KC, Murphy A, Molloy DJ, Herald DL, Williams MD, Pettit RK, Doubek DL, Hooper JNA, Albright L, Schmidt JM, Chapuis JC, Tackett LP (2004) Antineoplastic agents. 380. Isolation and x-ray crystal structure determination of isoaaptamine from the Republic of Singapore *Hymeniacidon* sp. and conversion to the phosphate prodrug hystatin 1. J Nat Prod 67:506–509
21. Larghi EL, Bohn ML, Kaufman TS (2009) Aaptamine and related products. Their isolation, chemical syntheses, and biological activity. Tetrahedron 65:4257–4282
22. Aoki S, Kong D, Suna H, Sowa Y, Sakai T, Setiawan A, Kobayashi M (2006) Aaptamine, a spongean alkaloid, activates p21 promoter in a p53-independent manner. Biochem Biophys Res Commun 342:101–106
23. Fedoreev SA, Prokof'eva NG, Denisenko VA, Rebachuk NM (1988) Cytotoxic activity of aaptamines from suberitid marine sponges. Pharm Chem J 22:615–618
24. Gul W, Hammond NL, Yousaf M, Bowling JJ, Schinazi RF, Wirtz SS, Andrews GC, Cuevas C, Hamann MT (2006) Modification at the C9 position of the marine natural product isoaaptamine and the impact on HIV-1, mycobacterial, and tumor cell activity. Bioorg Med Chem 14:8495–8505
25. Pettit GR, Hoffmann H, Herald DL, Blumberg PM, Hamel E, Schmidt JM, Chang Y, Pettit RK, Lewin NE, Pearce LV (2004) Antineoplastic agents. 499. Synthesis of hystatin 2 and related 1H-benzo[de][1,6]-naphthyridinium salts from Aaptamine. J Med Chem 47:1775–1782
26. Wayne LG, Hayes LG (1996) An in vitro model for sequential study of shift down of *Mycobacterium tuberculosis* through two stages of nonreplicating persistence. Infect Immun 64:2062–2069

https://unila.turnitin.com/viewer/submissions/oid:7867:12757419/print?locale=en 7/7